Dawe K, Hutchings P, Champion B, Cooke A, Roitt I
Department of Immunology, University College and Middlesex School of Medicine, London, UK.
Springer Semin Immunopathol. 1993;14(3):285-307. doi: 10.1007/BF00195979.
The autoantigens involved in autoimmune thyroid disease have now been extensively characterised, and the autoantibodies they evoke provide important aids to diagnosis, leading to early treatment of thyroid autoimmunity. The next stage in the puzzle is to determine towards which epitopes on the autoantigens the immune response is directed. We have already come a long way in the identification of immunodominant epitopes and have been able to identify one T cell epitope which has pathogenic capabilities. Identification of other T cell and B cell epitopes will help us understand the cell-mediated and humoral responses in greater detail and in time lead to more specific therapeutic intervention. A greater understanding of the mechanisms underlying one particular autoimmune disease will give us insights into other diseases, due to the belief that there may well be common underlying defects that, due to a multitude of factors, manifest as different diseases. The susceptibility factors in autoimmune thyroidits and autoimmune disease in general are very complex. A greater understanding is required of HLA associations and how particular peptides are presented in vivo. Are susceptible MHC types the ones capable of presenting the pathogenic peptides? Our major T cell thyroiditogenic epitope contains a T4 residue which accounts for over half the molecular weight of the peptide. Its structure is large and consists of a double benzene ring structure with four iodine atoms. It will be interesting to see how such a peptide can be presented and which residues bind T cell receptor or MHC. In summary we can say that autoimmune disease is due to a cocktail of factors which all contrive to tip the delicate balance of the immune system into an autoimmune state. HLA association may play a role in conferring an enhanced ability to select from a restricted repertoire of pathogenic epitopes, those epitopes perhaps only becoming available for presentation after interaction with environmental agents, whatever they may be. Following this, the normal regulation of self presentation and tolerance mechanisms break down and autoimmunity supervenes.
目前,自身免疫性甲状腺疾病所涉及的自身抗原已得到广泛表征,它们引发的自身抗体为诊断提供了重要帮助,从而实现甲状腺自身免疫的早期治疗。难题的下一阶段是确定免疫反应针对自身抗原上的哪些表位。我们在确定免疫显性表位方面已经取得了很大进展,并且已经能够鉴定出一个具有致病能力的T细胞表位。鉴定其他T细胞和B细胞表位将有助于我们更详细地了解细胞介导和体液反应,并及时导致更具特异性的治疗干预。对一种特定自身免疫性疾病潜在机制的更深入理解将使我们对其他疾病有所洞察,因为人们认为很可能存在共同的潜在缺陷,由于多种因素,这些缺陷表现为不同的疾病。自身免疫性甲状腺炎以及一般自身免疫性疾病中的易感因素非常复杂。需要更深入地了解HLA关联以及特定肽在体内的呈递方式。易感的MHC类型是那些能够呈递致病肽的类型吗?我们主要的甲状腺致炎T细胞表位包含一个T4残基,其占该肽分子量的一半以上。它的结构很大,由带有四个碘原子的双苯环结构组成。看看这样一个肽如何被呈递以及哪些残基与T细胞受体或MHC结合将会很有趣。总之,我们可以说自身免疫性疾病是由于多种因素共同作用,导致免疫系统的微妙平衡向自身免疫状态倾斜。HLA关联可能在赋予从有限的致病表位库中进行选择的增强能力方面发挥作用,这些表位可能只有在与环境因素(无论它们是什么)相互作用后才可供呈递。在此之后,自身呈递和耐受机制的正常调节就会瓦解,自身免疫就会接踵而至。